C-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Campone, Mario ^a,b   Noël, Bélinda ^a,b   Couriaud, Cécile ^a   Grau, Morgan ^a   Guillemin, Yannis ^a   Gautier, Fabien ^a,b   Gouraud, Wilfried ^b,c   Charbonnel, Catherine ^b,c   Campion, Loïc ^b,c   Jézéquel, Pascal ^b,c   Braun, Frédérique ^a   Barré, Benjamin ^a,b   Coqueret, Olivier ^a,b   Barillé Nion, Sophie ^a   Juin, Philippe ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b CLCC René Gauducheau ^*  (France)

^c CHU de Nantes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PUMA PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; BCL2L1 PROTEIN, HUMAN; DRUG DERIVATIVE; EVEROLIMUS; HER2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTORC1 COMPLEX, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN; PROTEIN BCL X; RAPAMYCIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; REGULATORY MECHANISM; WESTERN BLOTTING; BREAST TUMOR; CELL AGGREGATION; CELL SURVIVAL; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BREAST NEOPLASMS; CELL AGGREGATION; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 80052573201     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-110     Document Type: Article

References (42)

1. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl 2):1-13.
2. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin B, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 1996, 15:2452-67. 450177, 8665853.
3. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-45. 10.1101/gad.1212704, 15314020.
4. Le X, Pruefer F, Bast R. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005, 4:87-95. 10.4161/cc.4.1.1360, 15611642.
5. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler L, Sonenberg N. eIF4E--from translation to transformation. Oncogene 2004, 23:3172-9. 10.1038/sj.onc.1207549, 15094766.
6. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005, 280:10964-73. 10.1074/jbc.M407874200, 15634685.
7. Miller T, Forbes J, Shah C, Wyatt S, Manning H, Olivares M, Sanchez V, Dugger T, de Matos Granja N, Narasanna A, Cook R, Kennedy J, Lindsley C, Arteaga C. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009, 15:7266-76. 10.1158/1078-0432.CCR-09-1665, 2787848, 19934303.
8. O'Rourke D, Kao G, Singh N, Park B, Muschel R, Wu C, Greene M. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci USA 1998, 95:10842-7. 10.1073/pnas.95.18.10842, 27983, 9724792.
9. Yu D, Liu B, Jing T, Sun D, Price J, Singletary S, Ibrahim N, Hortobagyi G, Hung M. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998, 16:2087-94. 10.1038/sj.onc.1201729, 9572489.
10. Sharma S, Gajowniczek P, Way I, Lee D, Jiang J, Yuza Y, Classon M, Haber D, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10:425-35. 10.1016/j.ccr.2006.09.014, 2673136, 17097564.
11. Evan G. Can't kick that oncogene habit. Cancer Cell 2006, 10:345-7. 10.1016/j.ccr.2006.10.013, 17097554.
12. Campone M, Juin P, André F, Bachelot T. Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol Hematol 2010,
13. Juin P, Geneste O, Raimbaud E, Hickman J. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta 2004, 1644:251-60. 10.1016/j.bbamcr.2003.10.010, 14996507.
14. Letai A. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008, 8:121-32. 10.1038/nrc2297, 18202696.
15. Gallenne T, Gautier F, Oliver L, Hervouet E, Noël B, Hickman JA, Geneste O, Cartron P, Vallette FM, Manon S, Juin P. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 2009, 185:279-290. 10.1083/jcb.200809153, 2700382, 19380879.
16. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H, Reed J. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994, 145:1323-36. 1887502, 7992838.
17. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed J. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995, 146:1309-19. 1870904, 7778670.
18. Henson E, Hu X, Gibson S. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006, 12:845-53. 10.1158/1078-0432.CCR-05-0754, 16467098.
19. Sunters A, Fernandez de Mattos S, Stahl M, Brosens J, Zoumpoulidou G, Saunders C, Coffer P, Medema R, Coombes R, Lam E. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003, 278:49795-805. 10.1074/jbc.M309523200, 14527951.
20. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004, 22:4217-4226. 10.1200/JCO.2004.01.103, 15483033.
21. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70:709-718. 10.1158/0008-5472.CAN-09-1681, 20068161.
22. Barré B, Perkins ND. The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol Cell 2010, 38:524-538. 10.1016/j.molcel.2010.03.018, 20513428.
23. Ma X, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616. 10.1016/j.ccr.2004.05.015, 15193263.
24. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.
25. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24:4236-4244. 10.1200/JCO.2006.05.6861, 16896004.
26. Calabrò A, Beissbarth T, Kuner R, Stojanov M, Benner A, Asslaber M, Ploner F, Zatloukal K, Samonigg H, Poustka A, Sültmann H. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 2009, 116:69-77. 10.1007/s10549-008-0105-3, 18592372.
27. Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin A, Bataille R, Campion L. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat 2009, 116:509-520. 10.1007/s10549-008-0250-8, 19020972.
28. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hausler S, Ossadnik M, Krockenberger M, Beier D, Beier C, Dietl J, Becker J, Honig A, Wischhusen J. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 2009, 69:8058-66. 10.1158/0008-5472.CAN-09-0834, 19826050.
29. Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R, Lander E. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-59. 10.1016/j.cell.2009.06.034, 19682730.
30. Juin P, Cartron P, Vallette F. Activation of Bax by BH3 domains during apoptosis: the unfolding of a deadly plot. Cell Cycle 2005, 4:637-42. 10.4161/cc.4.5.1671, 15846080.
31. Hemann M, Bric A, Teruya-Feldstein J, Herbst A, Nilsson J, Cordon-Cardo C, Cleveland J, Tansey W, Lowe S. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-11. 10.1038/nature03845, 16094360.
32. Romagnoli M, Desplanques G, Maiga S, Legouill S, Dreano M, Bataille R, Barille-Nion S. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res 2007, 13:6010-8. 10.1158/1078-0432.CCR-07-0140, 17947462.
33. Ouyang Z, Zhou Q, Wong WH. ChIP-Seq of transcription factors predicts absolute and differential gene expression in embryonic stem cells. Proc Natl Acad Sci USA 2009, 106:21521-21526. 10.1073/pnas.0904863106, 2789751, 19995984.
34. Schust J, Sperl B, Hollis A, Mayer T, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006, 13:1235-42. 10.1016/j.chembiol.2006.09.018, 17114005.
35. Yuan G, Qian L, Shi M, Lu F, Li D, Hu M, Yu M, Shen B, Guo N. HER2-dependent MMP-7 expression is mediated by activated STAT3. Cell Signal 2008, 20:1284-1291. 10.1016/j.cellsig.2008.02.017, 18411043.
36. Gatza M, Lucas J, Barry W, Kim J, Wang Q, Crawford M, Datto M, Kelley M, Mathey-Prevot B, Potti A, Nevins J. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010, 107:6994-9. 10.1073/pnas.0912708107, 2872436, 20335537.
37. Graff J, Konicek B, Carter J, Marcusson E. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008, 68:631-4. 10.1158/0008-5472.CAN-07-5635, 18245460.
38. Hsieh A, Costa M, Zollo O, Davis C, Feldman M, Testa J, Meyuhas O, Shokat K, Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-61. 10.1016/j.ccr.2010.01.021, 2901095, 20227039.
39. Schwickart M, Huang X, Lill J, Liu J, Ferrando R, French D, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang D, Dixit V. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-7. 10.1038/nature08646, 20023629.
40. Marx C, Held J, Gibson B, Benz C. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res 2010, 70:3709-17. 10.1158/0008-5472.CAN-09-3768, 2862137, 20406983.
41. Faber A, Li D, Song Y, Liang M, Yeap B, Bronson R, Lifshits E, Chen Z, Maira S, Garcia-Echeverria C, Wong K, Engelman J. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009, 106:19503-8. 10.1073/pnas.0905056106, 2765921, 19850869.
42. Gonzalez-Rodriguez A, Alba J, Zimmerman V, Kozma S, Valverde A. S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology 2009, 50:216-29. 10.1002/hep.22915, 2752632, 19437488.